HRMYHarmony Biosciences Holdings, Inc.

$40.31+24% 1Y

Is it safe?

Mixed

Forensics clean, with a caveat: a safe balance sheet and clean books, but big price swings.

3 good, 1 to watch, 2 neutral
SurvivalSafe zone

Financially healthy, low distress risk Altman Z-score, a bankruptcy-risk model from five balance-sheet ratios.

Honest booksLow risk

Reported earnings show no manipulation flags Beneish M-score, a forensic model that detects earnings-manipulation patterns (receivables outrunning sales, margins slipping, accrual-heavy profit).

Quality5 / 9

Mixed fundamental signals Piotroski F-score, nine pass/fail tests of year-over-year financial health across profitability, balance sheet and efficiency. 7 to 9 is strong, 0 to 3 weak.

Insider conviction-$3.1M

Insiders were net sellers (-$3.1M, 90 days to Oct 8, 2026), selling is often routine.

Credit gradeAAderived · Jun 30, 2026

Net cash and profitable. A rule of thumb on leverage, not a credit rating.

Drawdown risk45% volderived · Oct 9, 2026

Large price swings, high volatility. Worst drawdown -68% · now 6% below its 52-week high.

Unless marked, from SEC EDGAR, as of Dec 31, 2025.

Against the whole market›

Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.

Volatilitymiddle of the market
Max drawdownmiddle of the market

Where this answer is blind. Altman sits structurally low for utilities and pipelines; Beneish runs high for fast growers, since sales growth alone lifts it; banks and REITs are excluded.

Can HRMY take a bad year?

Harmony Biosciences Holdings, Inc. holds $514M more cash than debt, so a bad year is a question about profits, not about lenders.

$514M

Net cash

Net debt / EBITDA
net cash

Net debt / EBITDA · no net borrowings to measure against earnings

Altman Z-score
4.97

Altman Z-score · safe zone, above 3

Interest cover
17.1×

Interest cover · operating profit covers the interest bill several times over

Details›
Total debtQ2 2026
$154M
Cash and short-term investments
$668M
Net cash
$514M
Operating profit, trailing twelve months
$231M
Debt / equity
0.15×
Annualised volatilitytwo years of daily moves
45%
Worst drawdown on file
−68%
Below its 52-week high
6.0%

Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.

On our screens:Stocks with no debt